$ALT 0.56 Developing
- Date
- Jun 22, 2026
- Mentions
- 1
- Unique authors
- 1
- Sector
- biotech
- Stance
- bullish
- On card
- no
Sentiment history
bullish
neutral
mixed
bearish
line = signal
dashed = price
No sentiment history available for $ALT yet.
Sentiment
bullish 1
Notable posts
-
bullish 17 eng
Leerink initiated $ALT at Outperform with a $10 PT. The firm highlights pemvidutide, Altimmune’s once-weekly GLP-1/glucagon dual agonist for MASH, AUD and ALD. Leerink notes Phase 2b IMPACT showed statistically significant MASH resolution at 24 weeks, while ALT plans to start Phase 3 PERFORMA in 2H26, with 52-week biopsy data expected in 2029.
view on X →
Only one day of history so far — the signal arc fills in as the daily job runs.